The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

BIN1  -  bridging integrator 1

Homo sapiens

Synonyms: AMPH2, AMPHL, Amphiphysin II, Amphiphysin-like protein, Box-dependent myc-interacting protein 1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BIN1

  • Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features [1].
  • We propose that loss of BIN1 may contribute to breast cancer progression by eliminating a mechanism that restrains the ability of activated MYC to drive cell division inappropriately [2].
  • The purpose of this study is to investigate DNA profile of the BIN1 gene in human hepatoma Hep G2 cells, previously documented with lack of BIN1 expression [3].
  • Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma [4].
  • Exon 12A sequences abolished the ability of Bin1 to inhibit malignant transformation by c-Myc or adenovirus E1A [4].

High impact information on BIN1

  • Consistent with this likelihood, BIN1 inhibited malignant cell transformation by MYC [5].
  • Although BIN1 is expressed in many normal cells, its levels were greatly reduced or undetectable in 14/27 carcinoma cell lines and 3/6 primary breast tumours [5].
  • Bin1-induced apoptosis was inhibited in HepG2 cells expressing wild-type NS5A but not NS5A mutant with mutations in the SH3 binding motif [6].
  • Deletion and mutation analyses indicated that the SH3 binding motif of HCV NS5A and SH3 domain of Bin1 are essential for interaction [6].
  • Human hepatoma (HepG2) cells lacking expression of Bin1 undergo apoptosis upon infection with adeno-Bin1 [6].

Biological context of BIN1

  • 9-kilobase fragment from this region was sufficient for basal transcription and transactivation by MyoD, which may account for the high levels of BIN1 observed in skeletal muscle [7].
  • The 5'-flanking region of BIN1 is GC-rich and lacks a TATA box but directs transcriptional initiation from a single site [7].
  • Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing [7].
  • BIN1 (2q14) encodes multiple isoforms of a Myc-interacting adaptor protein that has features of a tumor suppressor, including the ability to inhibit Myc-mediated cell transformation and to promote apoptosis [1].
  • RESULTS: Four predominant BIN1 isoforms resulting from alternative splicing of exon 12A (a neural tissue-specific exon) and exon 13 (a Myc-binding domain encoding exon) were variably expressed in the 56 primary NBs [1].

Anatomical context of BIN1


Associations of BIN1 with chemical compounds

  • Furthermore, BIN1 transcript was identified in additional seven HCC cell lines analyzed [3].
  • RNA and immunohistochemical analyses indicated that Bin1 was expressed in most primary tumors, even at slightly elevated levels relative to benign tissues, but that it was frequently missing or inactivated by aberrant splicing in metastatic tumors and androgen-independent tumor cell lines [11].
  • Mutational analysis revealed that complex formation is primarily mediated by a proline-rich region in the C-terminal part of NS5A, which interacts with the amphiphysin II Src homology 3 domain [12].
  • Upon an AMPH 2 administration, periadolescents exhibited a much lower profile of locomotor hyperactivity than adults, and also failed to show an increase across the course of the session in CORT release, that was observed in adults [13].

Physical interactions of BIN1

  • BIN1 is a novel protein that interacts with the functionally critical Myc box regions at the N terminus of the MYC oncoprotein [5].
  • RIN3 was also capable of interacting via its Pro-rich domain with amphiphysin II, which contains SH3 domain and participates in receptor-mediated endocytosis [14].
  • RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway [14].
  • Here, we analyzed these sequences, which we term type II sequences, and show that the (257)LMDLA sequence in rat epsin 1 appears to be a weak clathrin-binding variant of the sequence (417)PWDLW originally found in human amphiphysin II [15].
  • Bin2 formed a stable complex in cells with Bin1, but not with amphiphysin, in a BAR domain-dependent manner [16].

Regulatory relationships of BIN1


Other interactions of BIN1

  • As we reported previously, BIN1 may function to circumvent MycN-mediated apoptosis in NBs with MYCN amplification [1].
  • The elucidation of clathrin as a splice-specific binding partner for amphiphysin II begins to address the potential functional role(s) for the multiple amphiphysin II splice variants and further supports an important function for clathrin-amphiphysin interactions in protein targeting during endocytosis [18].
  • We conclude that BIN1 is an MYC-interacting protein with features of a tumour suppressor [5].
  • Here we found that Exon10 also binds to the src homology 3 (SH3) domain of Bin1 itself, and hence blocks the binding of the SH3 domain to its canonical PxxP ligands, including dynamin [9].
  • We also show that the PLCdelta pleckstrin homology domain, another PI(4,5)P(2)-binding module, cannot substitute for Exon10 in Bin1 function in transverse tubule formation, and suggest the importance of the dual biochemical properties of Exon10 in myogenesis [9].

Analytical, diagnostic and therapeutic context of BIN1


  1. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Tajiri, T., Liu, X., Thompson, P.M., Tanaka, S., Suita, S., Zhao, H., Maris, J.M., Prendergast, G.C., Hogarty, M.D. Clin. Cancer Res. (2003) [Pubmed]
  2. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Ge, K., Duhadaway, J., Sakamuro, D., Wechsler-Reya, R., Reynolds, C., Prendergast, G.C. Int. J. Cancer (2000) [Pubmed]
  3. Investigation of the expression of Bin1, a putative suppressor, in human hepatoma cells. Livezey, K.W., Negorev, D., Simon, D. Cancer Genet. Cytogenet. (2000) [Pubmed]
  4. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Ge, K., DuHadaway, J., Du, W., Herlyn, M., Rodeck, U., Prendergast, G.C. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  5. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Sakamuro, D., Elliott, K.J., Wechsler-Reya, R., Prendergast, G.C. Nat. Genet. (1996) [Pubmed]
  6. Src homology 3 domain of hepatitis C virus NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Nanda, S.K., Herion, D., Liang, T.J. Gastroenterology (2006) [Pubmed]
  7. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. Wechsler-Reya, R., Sakamuro, D., Zhang, J., Duhadaway, J., Prendergast, G.C. J. Biol. Chem. (1997) [Pubmed]
  8. Amphiphysin II (SH3P9; BIN1), a member of the amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of ranvier in brain and around T tubules in skeletal muscle. Butler, M.H., David, C., Ochoa, G.C., Freyberg, Z., Daniell, L., Grabs, D., Cremona, O., De Camilli, P. J. Cell Biol. (1997) [Pubmed]
  9. Regulation of Bin1 SH3 domain binding by phosphoinositides. Kojima, C., Hashimoto, A., Yabuta, I., Hirose, M., Hashimoto, S., Kanaho, Y., Sumimoto, H., Ikegami, T., Sabe, H. EMBO J. (2004) [Pubmed]
  10. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Wechsler-Reya, R.J., Elliott, K.J., Prendergast, G.C. Mol. Cell. Biol. (1998) [Pubmed]
  11. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Ge, K., Minhas, F., Duhadaway, J., Mao, N.C., Wilson, D., Buccafusca, R., Sakamuro, D., Nelson, P., Malkowicz, S.B., Tomaszewski, J., Prendergast, G.C. Int. J. Cancer (2000) [Pubmed]
  12. Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein. Zech, B., Kurtenbach, A., Krieger, N., Strand, D., Blencke, S., Morbitzer, M., Salassidis, K., Cotten, M., Wissing, J., Obert, S., Bartenschlager, R., Herget, T., Daub, H. J. Gen. Virol. (2003) [Pubmed]
  13. A unique hormonal and behavioral hyporesponsivity to both forced novelty and d-amphetamine in periadolescent mice. Adriani, W., Laviola, G. Neuropharmacology (2000) [Pubmed]
  14. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. Kajiho, H., Saito, K., Tsujita, K., Kontani, K., Araki, Y., Kurosu, H., Katada, T. J. Cell. Sci. (2003) [Pubmed]
  15. Interaction of two structurally distinct sequence types with the clathrin terminal domain beta-propeller. Drake, M.T., Traub, L.M. J. Biol. Chem. (2001) [Pubmed]
  16. Bin2, a functionally nonredundant member of the BAR adaptor gene family. Ge, K., Prendergast, G.C. Genomics (2000) [Pubmed]
  17. BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification. Hogarty, M.D., Liu, X., Thompson, P.M., White, P.S., Sulman, E.P., Maris, J.M., Brodeur, G.M. Med. Pediatr. Oncol. (2000) [Pubmed]
  18. Multiple amphiphysin II splice variants display differential clathrin binding: identification of two distinct clathrin-binding sites. Ramjaun, A.R., McPherson, P.S. J. Neurochem. (1998) [Pubmed]
  19. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Wechsler-Reya, R., Elliott, K., Herlyn, M., Prendergast, G.C. Cancer Res. (1997) [Pubmed]
WikiGenes - Universities